Development of a Highly Tumor-Specific Adenovirus Vector

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$96,739.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA108023-01
Award Id:
70485
Agency Tracking Number:
CA108023
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
GENVEC, INC., 65 W WATKINS MILL RD, GAITHERSBURG, MD, 20878
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DAVID EINFELD
(240) 632-5542
Business Contact:
(240) 632-5537
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Despite a number of newly approved drugs, cancer is responsible for over 20% of all deaths and will soon overtake heart disease as the main killer in the Western world. First generation adenovirus vectors have shown promise in the treatment of locally advanced cancer via intratumoral administration. However, these first generation vectors are not likely to be suitable for treating large-market, metastatic cancers due to their limited efficiency and specificity. Therefore, the development of targeted adenovirus vectors that can efficiently and specifically deliver potent anti-cancer genes to disseminated tumors would be a major advance in the treatment of cancer. The preliminary data in this grant detail an adenovirus vector that is ablated for binding to its native receptors and redirected for binding to the highly tumor-selective receptor, alpha-v-beta-6. Compared to an untargeted vector, it is demonstrated that this vector significantly improved the specificity of gene transfer to a subcutaneous alpha-v-beta-6-expressing lung carcinoma. While the specificity of tumor gene transfer is dramatically improved, the data suggests that the specificity achieved by the vector may require further enhancement. Previous work has shown that modifications that ablate the binding of adenovirus to its native receptors, as highlighted above, are critical for improving specificity. However, recently published research has shown that additional modifications to the adenovirus vector that reduce the length and/or alter the composition of its elongated coat protein, fiber, also significantly reduce gene transfer to non-target organs and thereby improve specificity. The primary objective of this phase I SBIR is to further improve the specificity of the current tumor targeted vector through reducing the length of its fiber coat protein. The long-term objective of this application is to create a breakthrough cancer therapeutic for clinical development based upon an adenovirus vector that efficiently and specifically targets potent antitumor genes to metastatic tumors.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government